7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD

Differentiating PEW, Sarcopenia & Cachexia in CKD

Core Clinical Principle: Not all weight loss and muscle depletion in chronic kidney disease stem from the same biological mechanism. Prescribing isolated hypercaloric oral supplements to a patient with cytokine-driven cachexia or uremic PEW fails to halt muscle proteolysis unless systemic inflammation, uremic toxicity, and metabolic acidosis are concurrently resolved. In contrast, simple starvation responds immediately to caloric repletion. Accurate differential diagnosis is essential for effective clinical management.

Patients with Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD) suffer from an extraordinary prevalence of somatic wasting, functional disability, and frailty. Historically, terms such as "renal malnutrition," "uremic cachexia," and "sarcopenia" were used interchangeably, creating diagnostic confusion and ineffective clinical trials. Today, distinct international consensus definitions establish clear boundaries between four primary wasting conditions: Protein-Energy Wasting (PEW), Sarcopenia, Disease-Related Cachexia, and Simple Starvation.

---

1. Protein-Energy Wasting (PEW) in CKD

Formally defined in 2008 by the International Society of Renal Nutrition and Metabolism (ISRNM), PEW refers to the state of decreased body stores of protein and energy fuels (somatic muscle and adipose compartments) alongside depleted visceral proteins, specifically induced by kidney disease and uremic toxicity.

The ISRNM Diagnostic Criteria

To establish a confirmed diagnosis of PEW, a patient must satisfy at least one objective criterion across at least three of the four diagnostic categories:

┌────────────────────────────────────────────────────────────────────────┐
│                      ISRNM PEW Diagnostic Framework                    │
│         (Requires ≥ 1 criterion in ≥ 3 of the 4 categories)            │
├────────────────────────────────────────────────────────────────────────┤
│  1. Serum Chemistry:                                                   │
│     • Serum Albumin < 3.8 g/dL (bromocresol green method)              │
│     • Serum Prealbumin < 30 mg/dL (maintenance dialysis)               │
│     • Serum Total Cholesterol < 100 mg/dL (unintentional hypochol.)   │
│                                                                        │
│  2. Body Mass:                                                         │
│     • BMI < 23 kg/m²                                                   │
│     • Unintentional weight loss > 5% over 3 mo OR > 10% over 6 mo      │
│     • Total Body Fat < 10%                                             │
│                                                                        │
│  3. Muscle Mass:                                                       │
│     • Skeletal muscle mass loss > 5% over 3 mo OR > 10% over 6 mo      │
│     • Mid-Arm Muscle Circumference (MAMC) reduction > 10% vs median    │
│                                                                        │
│  4. Dietary Intake:                                                    │
│     • Low protein intake < 0.8 g/kg/d on dialysis (< 0.6 in CKD 2–5)   │
│     • Low energy intake: < 25 kcal/kg/d for ≥ 2 continuous months      │
└────────────────────────────────────────────────────────────────────────┘

Pathophysiological Hallmarks

PEW is driven by accelerated myofibrillar protein degradation through the ATP-dependent 26S ubiquitin-proteasome system (UPS), triggered by caspase-3 cleavage of actomyosin, metabolic acidosis (serum $\text{HCO}_3^- < 22$ mEq/L), gut-derived uremic toxins (indoxyl sulfate, p-cresyl sulfate), insulin resistance, and obligatory dialytic nutrient clearance (6–12 g free amino acids lost per HD treatment; 5–15 g protein lost daily in PD effluent).

---

2. Sarcopenia in Kidney Disease

Sarcopenia is a progressive and generalized skeletal muscle disorder involving the accelerated loss of muscle mass and muscle function. In nephrology, sarcopenia is accelerated by uremic myopathy, physical inactivity, mitochondrial decay, and motor unit denervation.

EWGSOP2 Consensus Staging Framework

The European Working Group on Sarcopenia in Older People 2 (EWGSOP2) framework utilizes a three-tiered diagnostic staging sequence:

Sarcopenic Obesity: The Lethal Phenotype

In maintenance dialysis, an elevated Body Mass Index (BMI $\ge 25\text{--}34.9$ kg/m²) is epidemiologically associated with improved survival—a phenomenon known as the obesity paradox or reverse epidemiology. However, sarcopenic obesity represents a critical clinical exception and the most dangerous body composition phenotype in nephrology.

• Definition: The coexistence of excess body fat (BMI $\ge 30$ kg/m², or body fat percentage $>25\%$ in men, $>35\%$ in women) with severe skeletal muscle depletion (low ASMMI) and functional weakness.
• Mechanism: Excess adipose tissue actively secretes pro-inflammatory cytokines (IL-6, TNF-α, leptin, resistin) and non-esterified fatty acids that infiltrate remaining skeletal myocytes (myosteatosis). Intramyocellular lipid accumulation impairs mitochondrial beta-oxidation and drives severe insulin resistance.
• Mortality Risk: Dialysis registry studies demonstrate that patients with sarcopenic obesity experience the highest cardiovascular and all-cause mortality rates of any subgroup, far exceeding patients with normal body composition or isolated non-sarcopenic obesity.

---

3. Disease-Related Cachexia

Cachexia is a complex metabolic syndrome associated with underlying chronic illness (such as ESRD, advanced congestive heart failure, cancer, or severe chronic obstructive pulmonary disease) characterized by an extreme loss of muscle with or without loss of fat mass.

Consensus Criteria (Evans et al.)

A formal diagnosis of cachexia requires unintentional non-edematous weight loss $\ge 5\%$ over 12 months (or BMI $<20$ kg/m² in the presence of chronic illness) PLUS at least three of the following five clinical criteria:

1. Decreased Muscle Strength: Handgrip strength in the lowest tertile.
2. Fatigue / Exhaustion: Inability to perform customary physical activities.
3. Anorexia: Markedly reduced food intake ($<20$ kcal/kg/day or $<70\%$ of normal energy intake).
4. Low Fat-Free Mass Index: Lean tissue depletion confirmed by DXA or skinfold anthropometry.
5. Abnormal Biochemistry: Evidence of active systemic inflammation (hs-CRP $>5.0$ mg/L), anemia (hemoglobin $<12.0$ g/dL), or visceral hypoalbuminemia (serum albumin $<3.2$ g/dL).

Cachexia vs. PEW: The Distinguishing Line

While PEW is specific to the uremic milieu of kidney disease and incorporates dialytic protein clearance and kidney-specific thresholds (e.g., nPCR $<0.8$ g/kg/d, BMI $<23$), cachexia represents the terminal hyper-inflammatory, hypercatabolic end-stage of chronic disease. Patients with cachexia exhibit marked, persistent elevations in inflammatory cytokines (hs-CRP frequently $>10\text{--}20$ mg/L, elevated circulating TNF-α), hypermetabolism, accelerated lipolysis, and severe neuroendocrine appetite failure mediated by central melanocortin activation.

---

4. Simple Starvation (Pure Malnutrition)

Simple starvation refers to involuntary or voluntary pure caloric and/or protein deprivation occurring in the absence of underlying systemic inflammation or hypercatabolism (e.g., food insecurity, mechanical dysphagia, isolated psychiatric anorexia).

Adaptive Metabolic Response

The human body possesses powerful neuroendocrine adaptations to simple starvation designed to prolong survival:

• Suppression of Resting Energy Expenditure (REE): REE decreases by 15–30% through down-regulation of thyroid hormone conversion (triiodothyronine [T3] to reverse T3) and sympathetic nervous system tone.
• Selective Adipose Mobilization: Lipolysis is upregulated to supply free fatty acids and ketone bodies (acetoacetate, beta-hydroxybutyrate) as fuel for the central nervous system, drastically sparing skeletal muscle protein breakdown.
• Conservation of Visceral Protein Synthesis: In simple starvation without inflammation, hepatic synthesis of albumin, prealbumin, and transferrin remains intact until terminal exhaustion. Therefore, serum albumin is often completely normal (e.g., 4.0–4.2 g/dL) in early-to-moderate starvation.
• Responsiveness to Feeding: Simple starvation is fully and rapidly reversible upon providing adequate dietary energy and protein, exhibiting none of the metabolic resistance seen in PEW or cachexia.

---

5. Master Differential Diagnosis Matrix

The following clinical matrix synthesizes the pathophysiological, biochemical, and functional distinctions essential for the CSR examination: